Skip to main content

Table 1 Patient demographics and baseline disease characteristics (safety population)

From: Pharmacokinetics of carfilzomib in patients with advanced malignancies and varying degrees of hepatic impairment: an open-label, single-arm, phase 1 study

Characteristics

Hepatic function

 

Normal

(n = 11)

Mild impairment

(n = 17)

Moderate impairment

(n = 14)

Severe impairment

(n = 4)

Total

(N = 46)

Sex, n (%)

 Male

9 (82)

9 (53)

9 (64)

1 (25)

28 (61)

Race, n (%)

     

 Black

0 (0)

1 (5.9)

1 (7)

0 (0)

2 (4)

 White

11 (100)

13 (76.5)

13 (93)

4 (100)

41 (89)

 Not reported

0 (0)

3 (17.6)

0 (0)

0 (0)

3 (7)

Age, years

     

 Median

69.0

59.0

62.5

54.5

63.5

 Range, min–max

55–78

37–74

47–70

45–71

37–78

 ≥65 years, n (%)

8 (72.7)

5 (29.4)

6 (42.9)

1 (25.0)

20 (43.5)

ECOG performance status, n (%)

 0 or 1

11 (100)

13 (76)

12 (86)

4 (100)

40 (87)

 2

0 (0)

4 (24)

2 (14)

0 (0)

6 (13)

Time from initial diagnosis to informed consent, years

 Median

3.75

2.95

2.34

2.78

2.82

 Min, max

0.8, 9.4

0.9, 16.4

0.7, 7.8

1.3, 4.0

0.7, 16.4

Current disease stage, n (%)

 3

0 (0)

0 (0)

3 (21)

1 (25)

4 (9)

 4

8 (73)

16 (94)

10 (71)

3 (75)

37 (80)

 Unknown

1 (9)

1 (6)

1 (7)

0 (0)

3 (7)

 Missing

2 (18)

0 (0)

0 (0)

0 (0)

2 (4)

  1. ECOG Eastern Cooperative Oncology Group, ITT intent-to-treat, max maximum, min minimum, SD standard deviation